Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB2 | O43741 | 1/20 | 0.67 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.67 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.67 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.67 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.67 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.67 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23982207 | 0.86 | PRKAB2 (0.52) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL19236026 | 0.84 | PRKAB2 (0.73) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL19236034 | 0.80 | PRKAB2 (1.00) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL29611296 | 0.80 | PRKAB2 (1.00) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL716606 | 0.80 | PRKAB2 (1.00) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL10001662 | 0.80 | PRKAB2 (1.00) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL9121390 | 0.80 | ALDH1A1 (0.45) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL22452057 | 0.80 | ADORA3 (0.55) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL9587879 | 0.80 | ADORA3 (0.46) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL24436940 | 0.80 | ADORA3 (0.55) | ADORA3ADORA1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4599048-A1 | COMPOSITIONS AND METHODS FOR SMALL MOLECULE BASED EXPANSION OF PLURIPOTENT STEM CELLS | Trailhead Biosystems Inc. (US) | 2025-08-13 | — | — | EP | claimed |
| EP-4569090-A2 | METHODS AND COMPOSITIONS FOR GENERATING OLIGODENDROCYTE PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2025-06-18 | — | — | EP | claimed |
| CN-119654404-A | Methods and compositions for producing oligodendrocyte progenitor cells | 特雷尔赫德生物系统股份有限公司 | 2025-03-18 | — | — | CN | claimed |
| WO-2024112806-A1 | GENERATION AND USE OF EPIGENETIC MAPS FOR DRUG DISCOVERY | MOONWALK BIOSCIENCES, INC. (US) | 2024-05-30 | — | — | WO | claimed |
| WO-2024063818-A9 | METHODS AND COMPOSITIONS FOR GENERATING OLIGODENDROCYTE PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. (US) | 2024-05-23 | — | — | WO | claimed |
| US-20240117302-A1 | COMPOSITIONS AND METHODS FOR SMALL MOLECULE BASED EXPANSION OF PLURIPOTENT STEM CELLS | TRAILHEAD BIOSYSTEMS INC. | 2024-04-11 | — | — | US | claimed |
| WO-2024076758-A1 | COMPOSITIONS AND METHODS FOR SMALL MOLECULE BASED EXPANSION OF PLURIPOTENT STEM CELLS | TRAILHEAD BIOSYSTEMS INC. (US) | 2024-04-11 | — | — | WO | claimed |
| WO-2024063818-A2 | METHODS AND COMPOSITIONS FOR GENERATING OLIGODENDROCYTE PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. (US) | 2024-03-28 | — | — | WO | claimed |
| US-20240043798-A1 | METHODS AND COMPOSITIONS FOR GENERATING OLIGODENDROCYTE PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. | 2024-02-08 | — | — | US | claimed |
| CN-116200330-A | Method for down-regulating MAPK8 expression to induce reprogramming of cells into mammary epithelial cells | 广西壮族自治区人民医院 | 2023-06-02 | — | — | CN | claimed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4599048-A1 | COMPOSITIONS AND METHODS FOR SMALL MOLECULE BASED EXPANSION OF PLURIPOTENT STEM CELLS | Trailhead Biosystems Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4569090-A2 | METHODS AND COMPOSITIONS FOR GENERATING OLIGODENDROCYTE PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2025103336-A1 | USE OF TRIACETYL-3-HYDROXYPHENYLADENOSINE IN PREPARATION OF MOTION SIMULATION DRUG | 中国医学科学院药物研究所 | 2025-05-22 | — | — | WO | disclosed |
| CN-119654404-A | Methods and compositions for producing oligodendrocyte progenitor cells | 特雷尔赫德生物系统股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-112979734-B | Crystal form of triacetyl-3-hydroxy phenyl adenosine, preparation method and application thereof | 北京谷神生命健康科技有限公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-116200330-A | Method for down-regulating MAPK8 expression to induce reprogramming of cells into mammary epithelial cells | 广西壮族自治区人民医院 | 2023-06-02 | — | — | CN | disclosed |
| EP-3466433-B1 | TRIACETYL-3-HYDROXYL PHENYL ADENOSINE FOR USE IN TREATING ACUTE VASCULAR INFLAMMATIONS | BEIJING GUSHEN LIFE HEALTH TECH CO LTD (CN) | 2022-09-07 | — | — | EP | disclosed |
| US-11324768-B2 | Applications of triacetyl-3-hydroxyl phenyl adenosine in treating vascular inflammations or improving vascular endothelium functions | JIANGSU TASLY DIYI PHARMACEUTICALS CO., LTD. (CN) | 2022-05-10 | — | — | US | disclosed |
| CN-114377136-A | Combined medicine for treating hyperlipemia and its use | 中国医学科学院药物研究所 | 2022-04-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11324768-B2 | Applications of triacetyl-3-hydroxyl phenyl adenosine in treating vascular inflammations or improving vascular endothelium functions | LIPG, ADORA2A, VCAM1 | PRKAB2 95/4885PRKAG1 128/4885PRKAA2 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.